Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Fish and Richardson
Cipla
Boehringer Ingelheim
Novartis
Baxter
Cerilliant
Medtronic
AstraZeneca

Generated: October 22, 2017

DrugPatentWatch Database Preview

Rofecoxib - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for rofecoxib and what is the scope of rofecoxib freedom to operate?

Rofecoxib
is the generic ingredient in one branded drug marketed by Merck and is included in two NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Rofecoxib has thirty-seven patent family members in thirty-one countries.

There are two drug master file entries for rofecoxib.

Summary for Generic Name: rofecoxib

US Patents:1
Tradenames:1
Applicants:1
NDAs:2
Drug Master File Entries: see list2
Bulk Api Vendors: see list72
Clinical Trials: see list39
Patent Applications: see list6,268
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:rofecoxib at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052-002May 20, 1999DISCNNoNo► Subscribe► SubscribeY► Subscribe
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-002May 20, 1999DISCNNoNo► Subscribe► SubscribeY► Subscribe
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-003Feb 25, 2000DISCNNoNo► Subscribe► SubscribeY► Subscribe
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-001May 20, 1999DISCNNoNo► Subscribe► SubscribeY► Subscribe
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052-001May 20, 1999DISCNNoNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: rofecoxib

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-002May 20, 1999► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052-002May 20, 1999► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052-002May 20, 1999► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-001May 20, 1999► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-003Feb 25, 2000► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052-002May 20, 1999► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-003Feb 25, 2000► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-001May 20, 1999► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
SUSPENSION;ORAL021052-001May 20, 1999► Subscribe► Subscribe
Merck
VIOXX
rofecoxib
TABLET;ORAL021042-002May 20, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: rofecoxib

Country Document Number Estimated Expiration
Brazil9709097► Subscribe
China1225010► Subscribe
Hungary9902889► Subscribe
Turkey9802345► Subscribe
South Korea100373622► Subscribe
European Patent Office0910368► Subscribe
Taiwan536404► Subscribe
Indonesia16921► Subscribe
Czech Republic9803738► Subscribe
Eurasian Patent Organization001596► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
UBS
QuintilesIMS
Argus Health
Covington
Fish and Richardson
Dow
Harvard Business School
Colorcon
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot